In another healthcare deal, Watson Pharmaceuticals Inc. agreed on June 17 to buy privately held Arrow Group, a generic pharmaceuticals company, for $1.75 billion in cash and stock. The Corona, Calif.-based buyer used a team led by R. Scott Shean and Adel Aslani-Far at Latham & Watkins LLP. Shean also advised Watson on its $1.9 billion acquisition of Andrx Corp. in 2006 and on its $184 million purchase of Makoff R&D Laboratories Inc. in 2000.

For antitrust counsel on the Arrow deal, Watson is using Steven Sunshine and Ingrid Vandenborre of Skadden, Arps, Slate, Meagher & Flom LLP. Paul Donofrio, Matt Miller and Chris Seiter of Bank of America Merrill Lynch advised Watson on the banking side.

Arrow tapped Andrew Nussbaum at Wachtell, Lipton, Rosen & Katz on the recommendation of a London investor and former investment banker. Steve Frank and Tom Monaghan of J.P. Morgan Securities Inc. gave banking advice to Arrow. Coincidentally, BofA's Miller had worked with Nussbaum when both were Wachtell associates.